# Cyclosporine For The Treatment Of COVID-19(+)

> **NCT04492891** · PHASE2 · COMPLETED · sponsor: **Bryan Burt, MD** · enrollment: 47 (actual)

## Conditions studied

- SARS (Disease)

## Interventions

- **DRUG:** Cyclosporine
- **OTHER:** Standard of Care Treatment

## Key facts

- **NCT ID:** NCT04492891
- **Lead sponsor:** Bryan Burt, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-23
- **Primary completion:** 2021-12-10
- **Final completion:** 2021-12-10
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2023-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04492891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04492891, "Cyclosporine For The Treatment Of COVID-19(+)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04492891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*